CSL Ltd Annual Report 2020

Some data points contained in this report have been summarised and grouped according to CSL’s key sustainability topics and provided over a three-year period. Performance indicator More in this report (page reference) Measure 17-18 18-19 19-20 Economic contribution Operating revenue 7 US$ million 7,915 *† 8,539 *† 9,151 *† Net profit US$ million 1,729 *† 1,919 *† 2,103 *† Economic value generated 37 US$ million 7,925 *† 8,552 *† 9,158 *† Economic value distributed US$ million 7,500 *† 8,409 *† 8,832 *† Innovation R&D investment 21 US$ million 702 *† 832 *† 922 *† Our people Total headcount 44-47 Number 22,220 * 25,031 * 27,009 * Total Recordable Injury Frequency Rate (TRIFR) ‡ Per million hours worked 4.6 ** 7.2 ** 6.1 *† Fatalities (including contractors) Number 0 * 0 * 0 * Employee engagement Percentage 75 *† 74 *† 76.4 *† Safety and quality Regulatory audits 37 Number 374 † 440 † 401 † Quality audits of suppliers Number 489 † 580 † 476 † Safety related recalls of finished product Number 5 † 3 † 2 † Community Total contribution 48 US$ million 39.5 * 56.0 * 38.7 * Product access support (subset of total community contribution) 38 US$ million 7.5 *† 21.7 *† 6.6 *† Marketing and promotion Breaches 41 Number 0 *† 0 *† 2 *† Environment § Energy consumption 35 Petajoules 3.27 3.39 3.79 * Greenhouse gas emissions Metric kilotonnes 308 319 344 * Water consumption Gigalitres 3.61 3.87 4.25 * Waste Metric kilotonnes 49.15 61.40 66.75 * Waste recycling rate Percentage 43 42 46 * * Includes Ruide. † Data for nominated period has received limited assurance by Ernst & Young. ** Includes Ruide. Ernst & Young provided limited assurance against underlying data. ‡ See page 47 for more on reporting boundary. § See page 35 for more on reporting boundary. Reporting Boundary Our disclosure covers the businesses and operations over which we exercise direct control and incorporates CSL Limited, CSL Behring (including CSL Plasma), Seqirus, and global research and development (R&D), including Calimmune which was acquired in 2017. This includes our seven manufacturing facilities in Australia, Europe, the UK and the US as well as R&D, sales and marketing, distribution, and administration activities co-located with these facilities. Other R&D activities, sales and marketing, distribution, and administrative activities occurring away from our manufacturing facilities are also covered by this report, including the full network of donation centres, laboratories and administration offices operated by CSL Plasma. We continue to work towards fully integrating systems and processes for the acquired operations in China – plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide). Unless otherwise indicated, data for Ruide has been excluded. CSL’s acquisition of Vitaeris, announced in June 2020, is also excluded. CSL Limited Annual Report 2020 150 Key Performance Data Summary 16